biologic

Zenpep

pancrelipase

Loss of exclusivityJuly 2023projected — 12-year biologic exclusivity estimate
CompanyAimmune Therapeutics, Inc.

Drug detail

Brand nameZenpep
Active ingredientpancrelipase
Strength25,000USP UNITS; 79,000USP UNITS; 105,000USP UNITS
Dosage formCapsule, Delayed Release
RouteOral
ModalityBiologic
FDA approvalJuly 2011
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Zenpep patent cliff — loss of exclusivity July 2023 | CliffBio